Medicare Benefits Schedule - Note PN.0.35

The number of measurable residual disease (MRD) tests per patient, per episode of disease or per relapse is not expected to exceed 12, inclusive of a baseline assessment.

Related Items: 71202 73310

• Previous - Note PN.0.33
• Next - Note PN.1.1

Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist

Fee: $1,550.00 Benefit: 75% = $1,162.50 85% = $1,451.30

(See para PN.0.35 of explanatory notes to this Category)

Measurable residual disease (MRD) testing by flow cytometry, performed on bone marrow from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist

Fee: $550.00 Benefit: 75% = $412.50 85% = $467.50

(See para PN.0.35 of explanatory notes to this Category)